Thursday, 15 October 2026European Markets

ALPES (COMPAGNIE) And KID Have A High Dividend Yield And Return On Equity In The Consumer Cyclical Sector.

Loading stream...

(vianews) - alpes (compagnie) (cda.pa) is among this list of stock assets with the highest dividend rate and return on equity on the consumer cyclical sector.

financial asset price forward dividend yield return on equity
alpes (compagnie) (cda.pa) €12.70 6.87% 10.59%
kid (kid.ol) kr131.20 6.85% 26.8%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. alpes (compagnie) (cda.pa)

6.87% forward dividend yield and 10.59% return on equity

compagnie des alpes sa, together with its subsidiaries, engages in the operation of leisure facilities in france. the company operates through ski areas and leisure parks segments. the ski areas segment operates ski lifts; and maintains slopes. this segment also operates ski resorts. the leisure parks segment is involved in the operation of amusement parks, combined amusement and animal parks, water parks, waxwork museums, and tourist sites. compagnie des alpes sa was founded in 1989 and is headquartered in paris, france.

earnings per share

as for profitability, alpes (compagnie) has a trailing twelve months eps of €2.17.

pe ratio

alpes (compagnie) has a trailing twelve months price to earnings ratio of 5.85. meaning, the purchaser of the share is investing €5.85 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.59%.

volatility

alpes (compagnie)'s last week, last month's, and last quarter's current intraday variation average was a negative 0.66%, a negative 0.55%, and a positive 1.45%.

alpes (compagnie)'s highest amplitude of average volatility was 1.20% (last week), 1.28% (last month), and 1.45% (last quarter).

revenue growth

year-on-year quarterly revenue growth grew by 12.2%, now sitting on 1.21b for the twelve trailing months.

more news about alpes (compagnie).

2. kid (kid.ol)

6.85% forward dividend yield and 26.8% return on equity

kid asa, together with its subsidiaries, operates as a home textile retailer in norway, sweden, finland, and estonia. it designs, sources, markets, and sells a range of home and interior products, including textiles, curtains, bed linens, home accessories, decorations, furniture, and other interior products through retail stores and online platforms. the company provides its products under the kid, hemtex, dekosol, nordun, and premium collection brands. it also offers logistics services. the company was formerly known as nordisk tekstil holding as and changed its name to kid asa. kid asa was founded in 1937 and is headquartered in lier, norway.

earnings per share

as for profitability, kid has a trailing twelve months eps of kr8.65.

pe ratio

kid has a trailing twelve months price to earnings ratio of 15.17. meaning, the purchaser of the share is investing kr15.17 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.8%.

sales growth

kid's sales growth is 10.2% for the ongoing quarter and 7.5% for the next.

moving average

kid's worth is below its 50-day moving average of kr142.34 and above its 200-day moving average of kr130.14.

more news about kid.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com